Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara(Vanderbilt University), James E. Crowe(Vanderbilt University Medical Center), Swathi Shrihari(Washington University in St. Louis), Pavlo Gilchuk(AstraZeneca (Japan)), Laura A. VanBlargan(Washington University in St. Louis), Larissa B. Thackray(Washington University in St. Louis), Rachel S. Nargi(Vanderbilt University Medical Center), Elad Binshtein, Rita E. Chen(Washington University in St. Louis), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Edgar Davidson(Integral Molecular (United States)), Benjamin J. Doranz(Integral Molecular (United States)), Michael Diamond(Washington University in St. Louis), Elaine C. Chen(Vanderbilt University Medical Center), Seth J. Zost(Vanderbilt University Medical Center), Mallorie E. Fouch(Integral Molecular (United States)), Robert H. Carnahan(Vanderbilt University Medical Center), Emma S. Winkler(Washington University in St. Louis), Rachel E. Sutton(Vanderbilt University Medical Center)
Cited by 409
Related Papers
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k